- Home
- OPTN vs BWAY Comparison
OPTN vs BWAY Comparison
Compare OPTN & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- BWAY
- Stock Information
- Founded
- OPTN 2010
- BWAY 2003
- Country
- OPTN United States
- BWAY Israel
- Employees
- OPTN N/A
- BWAY N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- BWAY Medical/Dental Instruments
- Sector
- OPTN Health Care
- BWAY Health Care
- Exchange
- OPTN Nasdaq
- BWAY Nasdaq
- Market Cap
- OPTN 117.6M
- BWAY 136.9M
- IPO Year
- OPTN 2017
- BWAY 2019
- Fundamental
- Price
- OPTN $0.71
- BWAY $9.50
- Analyst Decision
- OPTN Strong Buy
- BWAY Buy
- Analyst Count
- OPTN 2
- BWAY 4
- Target Price
- OPTN $4.00
- BWAY $13.17
- AVG Volume (30 Days)
- OPTN 516.5K
- BWAY 91.8K
- Earning Date
- OPTN 11-07-2024
- BWAY 11-13-2024
- Dividend Yield
- OPTN N/A
- BWAY N/A
- EPS Growth
- OPTN N/A
- BWAY N/A
- EPS
- OPTN N/A
- BWAY 0.02
- Revenue
- OPTN $75,058,000.00
- BWAY $36,431,000.00
- Revenue This Year
- OPTN $24.44
- BWAY $378.91
- Revenue Next Year
- OPTN $49.00
- BWAY $20.27
- P/E Ratio
- OPTN N/A
- BWAY $249.81
- Revenue Growth
- OPTN 3.91
- BWAY 42.00
- 52 Week Low
- OPTN $0.65
- BWAY $3.09
- 52 Week High
- OPTN $2.10
- BWAY $9.70
- Technical
- Relative Strength Index (RSI)
- OPTN 33.40
- BWAY 69.44
- Support Level
- OPTN $0.65
- BWAY $8.71
- Resistance Level
- OPTN $0.70
- BWAY $9.70
- Average True Range (ATR)
- OPTN 0.05
- BWAY 0.41
- MACD
- OPTN -0.00
- BWAY 0.12
- Stochastic Oscillator
- OPTN 24.67
- BWAY 88.17
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.